Evidence map›Paper›PMID 38871849›Full record

ArticleScientific reports2024

Forward programming of hiPSCs towards beta-like cells using Ngn3, Pdx1, and MafA.

Abiramy Jeyagaran, Max Urbanczyk, Shannon L Layland, Frank Weise, Katja Schenke-Layland

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Islet Cell Replacement and Regeneration for Type 1 Diabetes: Current Developments and Future Prospects.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Abiramy JeyagaranInstitute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, Eberhard Karls University Tübingen, 72076, Tübingen, Germany.
Max UrbanczykInstitute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, Eberhard Karls University Tübingen, 72076, Tübingen, Germany.
Shannon L LaylandInstitute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, Eberhard Karls University Tübingen, 72076, Tübingen, Germany.
Frank WeiseNMI Natural and Medical Sciences Institute at the University Tübingen, 72770, Reutlingen, Germany.
Katja Schenke-LaylandInstitute of Biomedical Engineering, Department for Medical Technologies and Regenerative Medicine, Eberhard Karls University Tübingen, 72076, Tübingen, Germany. katja.schenke-layland@uni-tuebingen.de.

Funding

Deutsche Forschungsgemeinschaft INST 2388/33-1Horizon 2020 Framework Programme H2020-ITN 766181Ministerium für Wissenschaft, Forschung und Kunst Baden-Württemberg 33-729.55-3/214
6 · The paper itself

Abstract

Transplantation of stem cell-derived β-cells is a promising therapeutic advancement in the treatment of type 1 diabetes mellitus. A current limitation of this approach is the long differentiation timeline that generates a heterogeneous population of pancreatic endocrine cells. To address this limitation, an inducible lentiviral overexpression system of mature β-cell markers was introduced into human induced-pluripotent stem cells (hiPSCs). Following the selection of the successfully transduced hiPSCs, the cells were treated with doxycycline in the pancreatic progenitor induction medium to support their transition toward the pancreatic lineage. Cells cultured with doxycycline presented the markers of interest, NGN3, PDX1, and MAFA, after five days of culture, and glucose-stimulated insulin secretion assays demonstrated that the cells were glucose-responsive in a monolayer culture. When cultured as a spheroid, the markers of interest and insulin secretion in a static glucose-stimulated insulin secretion assay were maintained; however, insulin secretion upon consecutive glucose challenges was limited. Comparison to human fetal and adult donor tissues identified that although the hiPSC-derived spheroids present similar markers to adult insulin-producing cells, they are functionally representative of fetal development. Together, these results suggest that with optimization of the temporal expression of these markers, forward programming of hiPSCs towards insulin-producing cells could be a possible alternative for islet transplantation.

Indexed as

Basic Helix-Loop-Helix ProteinsCell DifferentiationHomeodomain ProteinsInduced Pluripotent Stem CellsInsulin-Secreting CellsMaf Transcription Factors, LargeNerve Tissue ProteinsTrans-ActivatorsCells, CulturedDoxycyclineGlucoseHumansInsulinInsulin SecretionBasic Helix-Loop-Helix ProteinsDoxycyclineGlucoseHomeodomain ProteinsInsulinMAFA protein, humanMaf Transcription Factors, LargeNerve Tissue ProteinsNEUROG3 protein, humanpancreatic and duodenal homeobox 1 proteinTrans-Activators

Identifiers

PMID38871849
PMCPMC11176171

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.